<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url><loc>https://ourglp1.com/news/glp1-libido-relationships-evidence</loc><news:news><news:publication><news:name>OurGLP1</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-29T21:00:00+01:00</news:publication_date><news:title>Do GLP-1 medicines affect libido or relationships? What the evidence shows</news:title></news:news></url>
  <url><loc>https://ourglp1.com/news/muscle-preservation-next-generation-obesity-treatment</loc><news:news><news:publication><news:name>OurGLP1</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-29T12:00:00+01:00</news:publication_date><news:title>Muscle preservation is becoming a new focus in obesity-drug research</news:title></news:news></url>
  <url><loc>https://ourglp1.com/news/glp1-news-roundup-retatrutide-orforglipron-naion</loc><news:news><news:publication><news:name>OurGLP1</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-29T10:00:00+01:00</news:publication_date><news:title>GLP-1 news roundup: Retatrutide Phase 3 results, an oral approval and new eye warnings</news:title></news:news></url>
</urlset>
